Navigation Links
Quest Diagnostics Reports Second Quarter 2013 Financial Results
Date:7/18/2013

iagnostic information services revenues decreased 3.6%. Volume, measured by the number of requisitions, increased 0.1% versus the prior year. Recent acquisitions added about 1.6% to volume and approximately 1.1% to revenue growth. Revenue per requisition was 3.7% below the prior year. Reduced reimbursement contributed approximately 3.2% of the reduction, and the business mix impact of our recent toxicology acquisition contributed the balance. 

For the second quarter of 2013, adjusted operating income from continuing operations was $308 million, or 16.9% of revenues, compared to $349 million, or 18.6% of revenues, for 2012. For the second quarter of 2013, reported operating income from continuing operations was $289 million, or 15.9% of revenues, compared to $333 million, or 17.7% of revenues, in 2012. Cash provided by operations was $208 million, compared to $251 million in the second quarter of 2012. 

Steve Rusckowski, President and CEO, commented: "As expected, revenues and earnings improved from first quarter levels, but were down versus the prior year. We saw continued revenue softness in the second quarter compared to the prior year due to lower healthcare utilization and reductions in reimbursement. As we've previously shared, 2013 is a building year; we are making good progress executing our five point strategy; and we expect stronger performance in the second half. The improvement in the second half is expected to be driven by: easier comparisons; the impact of acquisitions; the benefit of investments we have made to drive growth; and the excellent progress we're making with our Invigorate cost-reduction initiative.

"Additionally, we are making very good progress delivering disciplined capital deployment. During the quarter, we completed the acquisitions of the lab outreach business of Dignity Health and Concentra's toxicology business, which is consistent with our goal of contributing 1% to 2% revenue growth per year through
'/>"/>

SOURCE Quest Diagnostics Incorporated
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related biology technology :

1. Quest Diagnostics CE Marks Simplexa™ Test for Cytomegalovirus for Sale in Europe
2. Questcor Pharmaceuticals to Present at the Oppenheimer Healthcare Conference on December 13, 2011
3. A 50-year quest to isolate the thermoelectric effect is now over: Magnon drag unveiled
4. Survey Reveals Paternity Questions Loom for More Than One in 10 Americans
5. S.E.D. Labs to be Acquired by Quest Diagnostics
6. Quest Diagnostics STRATIFY JCV™ First FDA Market Authorized Antibody-based Blood Test to Help Stratify PML Risk in Multiple Sclerosis Patients
7. Quest Diagnostics Reports Fourth Quarter 2011 Financial Results; Provides Guidance for 2012
8. Questcor Pharmaceuticals to Present at the Leerink Swann Global Healthcare Conference on February 16, 2012
9. Mars, Incorporated Answers Question: How Does Feeding People and Pets Nurture Science and Discovery? At TEDMED 2012
10. Quest Diagnostics Announces C9orf72 Genetic Test for ALS (Lou Gehrigs Disease)
11. Questcor Pharmaceuticals Expands Repurchase Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... 2014 Global Record Systems, LLC, ... technology solutions for patients, physicians, the biopharmaceutical industry, ... today the signing of a three-year Research Collaboration ... Administration (FDA). This initiative is designed to ...
(Date:1/14/2014)... 13, 2014 Bob Hainsey, a semiconductor ... 20 years in the industry, has joined SPIE, ... will serve as the society’s Science and Technology Strategist. ... SPIE as our Technology Strategist, further strengthening the technical ...
(Date:1/14/2014)... During the 1600’s through the 1800’s doctors contributed ... In this time period, doctors did not know that they ... the death of vulnerable patients. In the same way, medical ... be unwittingly transmitting herpes viruses to their patients. The CBCD ...
(Date:1/14/2014)... Triangle Park, NC (PRWEB) January 14, 2014 ... company focusing on ultra-sensitive POC diagnostic platforms and novel disease ... their first round of financing netting a total of $690,000. ... outside equity capital in the company. This group of private ...
Breaking Biology Technology:Global Record Systems Announces Research Collaboration Agreement with FDA to Create a Novel “Big Data” Paradigm for Collection of Patient Safety and Outcomes Information 2Photonics R&D Leader Bob Hainsey Joins SPIE Technical Staff 2Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 2Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 3BioMedomics, Inc. Closes $690K Round of Financing 2
... 11 Alimera Sciences Inc., a privately held,biopharmaceutical ... of prescription ophthalmic pharmaceuticals, today reported,that enrollment has ... safety and efficacy,of Iluvien(TM) in patients with bilateral ... , The ...
... Shareholder Value , , CHICAGO, Dec. ... affiliates, of nearly 29% of the outstanding shares of common stock ... it had delivered a letter to Avigen,s Board of Directors expressing ... value. , , The ...
... today that they continue to penetrate and build market share in ... energy by working with companies like Southwest Windpower, MiaSole, Solyndra, Santur ... ... December 11, 2008 -- DAZ Systems, Inc. , announced today ...
Cached Biology Technology:Alimera Sciences Begins Pilot Study to Assess Safety and Efficacy of Iluvien(TM) in Patients With Bilateral Geographic Atrophy Due to AMD 2Biotechnology Value Fund Delivers Letter to Board of Directors of Avigen, Inc. 2Biotechnology Value Fund Delivers Letter to Board of Directors of Avigen, Inc. 3Biotechnology Value Fund Delivers Letter to Board of Directors of Avigen, Inc. 4Biotechnology Value Fund Delivers Letter to Board of Directors of Avigen, Inc. 5DAZ Systems, Inc. Thrives in the Clean Energy Industry 2DAZ Systems, Inc. Thrives in the Clean Energy Industry 3
(Date:4/17/2014)... infection , Respiratory syncytial virus (RSV) is ... generating life-threating illness in very young and elderly ... RSV enters host cells through the fusion protein ... Small interfering peptides that prevent bundle formation limit ... highly susceptible to degradation. In this issue of ...
(Date:4/17/2014)... modeling study suggests that fish consumption advisories for ... to long-lived contaminants like persistent organic pollutants (POPs). ... of researchers including University of Toronto Scarborough PhD ... at how different levels of environmental contamination, a ... chemicals in the body influenced exposure in her ...
(Date:4/17/2014)... Our eyes not ... with a continuous stream of information about our own movements. ... a car the world glides by us and leaves ... our brain calculates self-motion from this "optic flow". This way, ... during our own movements. Together with biologists from the University ...
Breaking Biology News(10 mins):JCI online ahead of print table of contents for April 17, 2014 2JCI online ahead of print table of contents for April 17, 2014 3JCI online ahead of print table of contents for April 17, 2014 4JCI online ahead of print table of contents for April 17, 2014 5JCI online ahead of print table of contents for April 17, 2014 6Fish consumption advisories fail to cover all types of contaminants 2How vision makes sure that little fish do not get carried away 2How vision makes sure that little fish do not get carried away 3How vision makes sure that little fish do not get carried away 4
... patients with epilepsy carry might enable doctors to better ... seizures, suggest basic findings by researchers at the Duke ... the University College London. Patients often undergo a lengthy ... of anti-epilepsy drugs appropriate for them. , The researchers ...
... lymphocytic leukemia (B-CLL),is the most common leukemia in ... mature B lymphocytes in the blood, bone,marrow, and ... early stages,of disease, B-CLL is the result of ... normal B cell death (apoptosis). Livio,Trentin and colleagues ...
... expert manipulators when it comes to co-opting their host's ... from the vast repertoire of proteins and mechanisms dedicated ... like HIV have evolved myriad ways of redirecting that ... eukaryotes have three types of RNA polymerases, each charged ...
Cached Biology News:Gene variations explain drug dose required to control seizures 2Gene variations explain drug dose required to control seizures 3Gene variations explain drug dose required to control seizures 4An HIV Protein Plays a Surprising Role in Gene Activation 2An HIV Protein Plays a Surprising Role in Gene Activation 3